Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Hematology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
EAHAD 2026: Nine-Year Outcomes of Gene Therapy
February 2026
Nine-year data show sustained safety and reduced bleeding after gene therapy in haemophilia B, although enrichment for full viral capsids did not deliver clear clinical advantages.
Read more
6 Jun 2025
Lower Transfusion Thresholds May Be Safe for Children Post-Transplant
A new UK clinical trial has found that children undergoing stem cell transplants may safely receive fewer blood transfusions.
4 Jun 2025
Hema Now: Episode 18: Myeloma Genetics, CAR-T, and Emerging Immunotherapies
Rafael Fonseca, Consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona, USA
3 Jun 2025
Genomic Study Offers Breakthrough in Predicting Multiple Myeloma Progression
23 May 2025
COMy 2025: Infection Risk High with Bispecific Antibodies in Myeloma
New research from COMy 2025 reveals a high rate of infections among people with relapsed or refractory multiple myeloma receiving bispecific antibodies…
23 May 2025
COMy 2025: Senescence Biomarkers Predict Frailty and Survival in Myeloma
New research, from COMy 2025, has found that specific senescence-associated biomarkers are significantly correlated with frailty and overall survival in newly diagnosed multiple myeloma.
22 May 2025
Hema Now: Episode 17: What Drives Change in Leukaemia Cells?
Paolo Gallipoli, Clinical Reader, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London joins the podcast to discuss the biology, onset, and treatment of myeloid leukaemias.
22 May 2025
COMy 2025: CAR-T Cell Therapy Access Gaps in Myeloma
At COMy 2025, researchers highlighted barriers to EMA-approved CAR-T cell therapy access due to age, comorbidities, and inequality.
22 May 2025
COMy 2025: Dual Testing After Transplant Predicts Better Myeloma Outcomes
A study presented at COMy 2025 found that dual MRD testing with bone marrow flow cytometry and PET/CT imaging better predicts progression-free survival in patients with multiple myeloma after autologous stem cell transplantation.
Loading posts...
« Previous
1
…
16
17
18
19
20
…
100
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View